BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists

Estrogen antagonists are universally employed in the breast cancer therapy, although antagonist therapy is limited by the inevitable development of cellular resistance. The molecular mechanisms by which these agents inhibit cellular proliferation in breast cancer cells are not fully defined. Recent...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	EMBO J
Autori principali:	Wang, Sheng, Zhang, Baohua, Faller, Douglas V
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Publishing Group 2004
Soggetti:	Article
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC419909/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15141164/ https://ncbi.nlm.nih.govhttps://doi.org/10.1038/sj.emboj.7600231
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!